1987 No. 66

DANGEROUS DRUGS

Misuse of Drugs (Designation) Order (Northern Ireland) 1987

Made . . . . . *18th February 1987*

Coming into operation . . *1st April 1987*

The Department of Health and Social Services in exercise of the powers conferred by section 7(4) and (5) of the Misuse of Drugs Act 1971(**a**) as adapted by section 7(9) of the Act and now vested in it(**b**) and of every other power enabling it in that behalf and on the recommendation of the Advisory Council on the Misuse of Drugs, hereby makes the following Order:—

Citation and commencement

1. This Order may be cited as the Misuse of Drugs (Designation) Order (Northern Ireland) 1987 and shall come into operation on 1st April 1987.

Interpretation

2. The Interpretation Act (Northern Ireland) 1954(**c**) shall apply to this Order as it applies to a Measure of the Northern Ireland Assembly.

Designation

3.—(1) The controlled drugs specified in Part 1 of the Schedule are hereby designated as drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies.

(2) Part II of the Schedule shall have effect for the purpose of specifying those controlled drugs which are excepted from Part 1.

Revocations

4. The Misuse of Drugs (Designation) Order (Northern Ireland) 1977(**d**) and the Misuse of Drugs (Designation) (Variation) Order (Northern Ireland) 1984(**e**) are hereby revoked.

Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on 18th February 1987.

(L.S.) *Z. I. Davies*

Under Secretary

(a) 1971 c. 38
(b) S.R. & O. (N.I.) 1973 No. 504 art. 5(*a*)
(c) 1954 c. 33 (N.I.)
(d) S.R. 1977 No. 291
(e) S.R. 1984 No. 364

SCHEDULE Article 3

PART I

CONTROLLED DRUGS TO WHICH SECTION 7(4) OF THE MISUSE OF DRUGS ACT 1971 APPLIES

1. The following substances and products, namely:—

(*a*) Bufotenine
Cannabinol
Cannabinol derivatives
Cannabis
Cannabis resin
Cathinone
Coca leaf
Concentrate of poppy-straw
Eticyclidine
Lysergamide
Lysergide and other *N*-alkyl derivatives of lysergamide
Mescaline
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2,5-dimethoxy-α-methyl-phenethylamine
N,*N*-Diethyltryptamine
N,*N*-Dimethyltryptamine
2,5-Dimethoxy-α,4-dimethyl-phenethylamine

(*b*) any compound (not being a compound for the time being specified in sub-paragraph (*a*)) structurally derived from tryptamine or from a ringhydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(*c*) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (*a*)) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α-methylphenethylamine, an *N*-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an *N*-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;

(*d*) any compound (not being a compound for the time being specified in Part II) structurally derived from fentanyl by modification in any of the following ways, that is to say,

(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi) by replacement of the *N*-propionyl group by another acyl group;

(*e*) any compound (not being a compound for the time being specified in Part II) that is structurally derived from pethidine by modification in any of the following ways, that is to say,

(i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;